$-0.24 EPS Expected for Marrone Bio Innovations (MBII); Gartner (IT)’s Sentiment Is 1.67

October 19, 2017 - By Adrian Erickson

Gartner, Inc. is an information technology research and advisory company. The company has market cap of $11.03 billion. The Firm works with clients to research, analyze and interpret the business of information technology , supply chain and marketing within the context of their individual roles. It has a 219.24 P/E ratio. It operates in three divisions: Research, Consulting and Events.

Analysts expect Marrone Bio Innovations Inc (NASDAQ:MBII) to report $-0.24 EPS on November, 13.They anticipate $0.05 EPS change or 17.24% from last quarter’s $-0.29 EPS. After having $-0.25 EPS previously, Marrone Bio Innovations Inc’s analysts see -4.00% EPS growth. It is down 94.03% since October 19, 2016 and is uptrending. It has outperformed by 77.33% the S&P500.

Marrone Bio Innovations, Inc. offers bio pest management and plant health products. The company has market cap of $30.72 million. The Company’s bio products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It currently has negative earnings. It sells its products to crop protection market.

Among 3 analysts covering Marrone Bio Innovations (NASDAQ:MBII), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Marrone Bio Innovations had 6 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating by Zacks given on Tuesday, August 11. On Friday, July 21 the stock rating was maintained by Piper Jaffray with “Hold”. The stock of Marrone Bio Innovations Inc (NASDAQ:MBII) earned “Buy” rating by Rodman & Renshaw on Wednesday, March 16. Piper Jaffray maintained the shares of MBII in report on Friday, September 15 with “Hold” rating. The stock of Marrone Bio Innovations Inc (NASDAQ:MBII) has “Hold” rating given on Monday, August 14 by Piper Jaffray. The company was maintained on Tuesday, August 15 by H.C. Wainwright.

Investors sentiment decreased to 0.86 in 2017 Q2. Its down 0.14, from 1 in 2017Q1. It dropped, as 3 investors sold Marrone Bio Innovations Inc shares while 4 reduced holdings. 1 funds opened positions while 5 raised stakes. 11.88 million shares or 32.33% more from 8.98 million shares in 2017Q1 were reported. 300 were reported by Ogorek Anthony Joseph New York Adv. Vanguard Group stated it has 314,908 shares or 0% of all its holdings. State Street stated it has 0% in Marrone Bio Innovations Inc (NASDAQ:MBII). 10,000 were reported by Hanson Mcclain Incorporated. 4.71 million are held by Waddell And Reed Fincl. Savant Ltd Liability owns 11,067 shares. Ardsley Advisory Partners stated it has 3.68M shares or 0.81% of all its holdings. 2.70M were accumulated by Primecap Management Comm Ca. Bridgeway Cap Mgmt holds 0% or 154,908 shares in its portfolio. 2,000 were accumulated by Creative Planning. Morgan Stanley invested 0% of its portfolio in Marrone Bio Innovations Inc (NASDAQ:MBII). Northern Trust Corp has 24,738 shares for 0% of their portfolio. Blackrock Incorporated holds 0% or 79,000 shares in its portfolio. Spark Limited Co holds 0% or 60,800 shares in its portfolio. Raymond James Financial has 16,961 shares for 0% of their portfolio.

Analysts await Gartner Inc (NYSE:IT) to report earnings on November, 2. They expect $0.58 EPS, 0.00% or $0.00 from last year’s $0.58 per share. IT’s profit will be $52.57 million for 52.46 P/E if the $0.58 EPS becomes a reality. After $0.88 actual EPS reported by Gartner Inc for the previous quarter, Wall Street now forecasts -34.09% negative EPS growth.

About 23,479 shares traded. Gartner Inc (IT) has risen 15.57% since October 19, 2016 and is uptrending. It has underperformed by 1.13% the S&P500.

Ratings analysis reveals 100% of Gartner’s analysts are positive. Out of 4 Wall Street analysts rating Gartner, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $108.0 while the high is $115.0. The stock’s average target of $112 is -7.97% below today’s ($121.7) share price. IT was included in 4 notes of analysts from August 26, 2016. As per Friday, August 26, the company rating was initiated by Macquarie Research. RBC Capital Markets upgraded it to “Outperform” rating and $113.0 target in Friday, January 6 report. The company was upgraded on Monday, January 9 by Barclays Capital. On Friday, January 6 the stock rating was upgraded by BMO Capital Markets to “Outperform”.

Since January 1, 0001, it had 0 buys, and 9 selling transactions for $6.79 million activity.